PXS announces positive interim data from myelofibrosis trial
Release Date: 19/10/2022 11:00am
Pharmaxis Ltd (ASX: PXS) held an online investor briefing by chief executive officer Mr Gary Phillips on October 19 2022.
The event consisted of an analysis of data from patients who have completed 6 months’ treatment with PXS-5505 in its Phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. Followed by a Q&A session from attendees. You can watch a recording of the presentation here.
The presentation slides are available in full here.
Categories: Video Content